Research ArticleImmunology

Histone Deacetylases 6 and 9 and Sirtuin-1 Control Foxp3+ Regulatory T Cell Function Through Shared and Isoform-Specific Mechanisms

See allHide authors and affiliations

Science Signaling  19 Jun 2012:
Vol. 5, Issue 229, pp. ra45
DOI: 10.1126/scisignal.2002873

Abstract

Therapeutic inhibition of the histone deacetylases HDAC6, HDAC9, or sirtuin-1 (Sirt1) augments the suppressive functions of regulatory T cells (Tregs) that contain the transcription factor Foxp3 (Forkhead box P3) and is useful in organ transplant patients or patients with autoimmune diseases. However, it is unclear whether distinct mechanisms are involved for each HDAC or whether combined inhibition of HDACs would be more effective. We compared the suppressive functions of Tregs from wild-type C57BL/6 mice with those from mice with either complete or cell-specific deletion of various HDACs, as well as with those of Tregs treated with isoform-selective HDAC inhibitors. The improvement of Treg suppressive function mediated by inhibition of HDAC6, but not Sirt1, required an intact heat shock response. Although HDAC6, HDAC9, and Sirt1 all deacetylated Foxp3, each protein had different effects on transcription factors that control expression of the gene encoding Foxp3. For example, loss of HDAC9, but not other HDACs, was associated with stabilization of the acetylated form of signal transducer and activator of transcription 5 (STAT5) and promoted its transcriptional activity. Thus, targeting different HDACs increased Treg function through multiple and additive mechanisms, which suggests the therapeutic potential for using combinations of HDAC inhibitors in the management of autoimmunity and organ transplantation.

Introduction

Autoimmune diseases and transplantation require therapeutic suppression of undesired immune responses. Ideally, suppression should be as limited and specific as possible, preserving the host’s ability to fight infections and cancer. Unfortunately, however, most current therapeutic regimens are unable to achieve this, causing an enormous burden of toxicity (1) and impairment of vital host immunity (2). Regulatory T cells (Tregs) constitute a T cell subset that is important for the attenuation of antigen-specific immune responses (3). Tregs are currently being evaluated for therapeutic applications, either through the direct administration of Tregs that were expanded in numbers ex vivo or through pharmacological measures aimed at selectively strengthening Treg function (4). Tregs are characterized by their expression of Forkhead box P3 (Foxp3), a transcription factor that plays a key role in their development and functions (5, 6). We showed that the suppressive capacity of murine and human Foxp3+ Tregs can be increased by exposure to inhibitors of histone/protein deacetylases (HDACs) (7, 8), as well as by deletion of HDAC9 (8), HDAC6 (9), or the class III HDAC sirtuin-1 (Sirt1) (10).

Such data suggest the potential for therapeutic targeting of combinations of HDAC enzymes; however, each HDAC deacetylates discrete sets of target proteins, and the mechanisms by which each enzyme regulates Treg function may be different (11). For example, a deficiency in HDAC6 markedly augments the heat shock response in Tregs (9), whereas deletion of Sirt1 may dampen the heat shock response in these cells, because Sirt1 is required to stabilize the heat shock factor 1 (HSF-1) trimer (12). As a result, combined inhibition of Sirt1 and HDAC6 might be counterproductive in efforts to promote the suppressive functions of Tregs. It is also unclear how important the heat shock response is to the increased Treg function observed when HDAC6 (or Sirt1) is targeted and whether there are heat shock response–independent mechanisms for the enhancement of Treg function by inhibiting HDAC6, such as control of Foxp3 acetylation, as was reported for HDAC9 (8) and Sirt1 (13, 14). Furthermore, deletion of HDAC6, HDAC9, or Sirt1 increases expression of the gene encoding Foxp3 (810); however, apart from data showing a role for nuclear factor κB (NF-κB) in the case of Sirt1 deletion in Tregs (10), the transcription factors involved in the enhanced suppressive functions of HDAC6−/− and HDAC9−/− Tregs are unknown. Therefore, we sought to investigate the mechanisms by which isotype-specific inhibition or deletion of HDACs affected Treg function with regard to the heat shock response, Foxp3 acetylation, and transcription factors relevant for Foxp3+ Tregs, as well as to assess whether the combined effects of targeting HDAC6, HDAC9, and Sirt1 on Treg function were additive, in vitro and in vivo. Our findings have implications for the future development of Treg therapies on the basis of HDAC inhibitors for anti-inflammatory and immune-mediated responses.

Results

Activation of the heat shock response is required for efficacy of HDAC6 targeting in Treg cells

We started our investigation by comparing the involvement and relative importance of the heat shock response in mouse models in which we tested how HDAC6 and Sirt1 inhibition could improve Treg function. Deletion of the genes encoding HDAC6 or HDAC9 led to hyperacetylation of Hsp90 at Lys294 (K294) in Tregs (Fig. 1A), in association with the nuclear translocation of HSF-1 (Fig. 1A, lower panel), and the induction of key heat shock response genes, such as those that encode Hsp27 and Hsp70 (9, 15). Although the exact mechanism remains unknown, a functioning heat shock response is considered important for the physiologic suppressive capabilities of Tregs (11). Consistent with this concept, we found that knockout of the gene encoding Hsp70 diminished the ability of wild-type Tregs to constrain T cell proliferation (Fig. 1B).

Fig. 1

The heat shock response is required to improve Treg function in response to inhibition of HDAC6, but not Sirt1. (A) Increased Hsp90 K294 acetylation (aHsp90) in HDAC6−/− Tregs (H6) and HDAC9−/− Tregs (H9), and to a lesser degree in fl-Sirt1/CD4cre Tregs (SC). Densitometry data are pooled from two experiments. Immunofluorescence of stimulated Tregs showed nuclear translocation of HSF-1, mostly in HDAC6−/− cells, whereas fl-Sirt1/CD4cre Tregs exhibited the least amount of intranuclear HSF-1. WT, wild type. (B) Hsp70−/− Tregs had diminished suppressive function. Data are from three experiments. (C) Hsp70−/− Tregs were less responsive to ACY-738 (HDAC6i) than WT Tregs, especially under conditions of heat shock. Data are from three experiments. (D) Sirt1-deficient Tregs exhibited a trend to increased acetylation of Hsp90 compared to WT Tregs. Densitometry data are pooled from two experiments. SF, fl-Sirt1/Foxp3cre. (E) Transcriptional repression of genes involved in the heat shock response in fl-Sirt1/CD4cre Tregs as analyzed by microarrays, with data shown after z score transformation. (F) Apoptosis-free survival of Tregs after heat shock. (G) The suppressive function of Tregs was improved by inhibition of Sirt1 (with EX-527) in the absence of Hsp70 and under conditions of heat shock. Data are from four experiments. Effector T cells (Teff) and APCs used in the suppression assays were from (B) WT or (C and G) Hsp70−/− mice. WT refers to the appropriate control mouse strain, that is, C57BL/6 mice for (A), (D), (E), and (F) or B6/129 mice for (B), (C), and (G). *P < 0.05; **P < 0.01; ***P < 0.001. ns, not significant. Scale bar, 10 μm. Additional statistics for (C) and (G) are available in tables S1 and S2.

Using standard or heat shock conditions, we next analyzed whether the effects of HDAC6 inhibition on Treg function were also dependent on the presence of Hsp70 in Tregs. Wild-type and Hsp70−/− Tregs were subjected to a 30-min heat shock (at 42°C), exposed to a previously uncharacterized HDAC6-selective inhibitor (HDAC6i), ACY-738 (fig. S1), and tested for their ability to suppress the proliferation of Hsp70−/− effector T cells that were costimulated with Hsp70−/− antigen-presenting cells (APCs) and monoclonal antibody (mAb) against CD3ε. We found that the HDAC6i enhanced the suppressive function of Tregs under standard conditions and after exposure to heat shock conditions (Fig. 1C). However, loss of Hsp70 substantially decreased the effects of HDAC6 inhibition on Tregs under standard conditions, and Hsp70−/− Tregs subjected to heat shock lost most of their responsiveness to HDAC6 inhibition (Fig. 1C and table S1). We conclude that activation of the heat shock response is required for the effect of HDAC6 inhibition in increasing the suppressive function of Tregs, but it is not the sole mechanism responsible.

Improving Treg function through inhibition of Sirt1 does not require activation of the heat shock response

Conditional CD4Cre- and Foxp3-Cre–mediated deletion of Sirt1 led to a modest increase in K294 acetylation in Hsp90 in the resulting Tregs (Fig. 1, A and D). However, in contrast to HDAC6−/− Tregs, deletion of Sirt1 did not result in nuclear translocation of HSF-1 (Fig. 1A). Consistent with these data, we found the reduced expression of numerous heat shock response genes in Sirt1−/− Tregs compared to those in wild-type Tregs (Fig. 1E). These observations led us to consider whether diminished transcription of genes involved in the heat shock response might decrease the resistance of Sirt1−/− Tregs to stress or affect their suppressive functions. We therefore exposed freshly isolated CD4+CD25+ Tregs from fl-Sirt1/CD4cre mice and wild-type mice to a heat shock similar to the conditions described earlier (Fig. 1C) and tested their ability to survive without initiating apoptosis or cell death, as determined by flow cytometric analysis of the amount of signal from annexin V and 7AAD (7-amino-actinomycin D), respectively. Compared to Tregs from wild-type mice, Tregs from fl-Sirt1/CD4cre mice showed improved survival, despite their lack of activation of genes involved in the heat shock response (Fig. 1F). Given that deletion of Sirt1 seemingly preserved the ability of Tregs to withstand cell stress despite the lack of expression of their heat shock response genes, we hypothesized that improved Treg function as a result of Sirt1 inhibition might be independent of the expression of genes involved in the heat shock response. Indeed, Hsp70−/− Tregs challenged by heat shock still exhibited a marked improvement in their suppressive capability in response to the Sirt1-specific inhibitor, EX-527 (Fig. 1G and table S2). We conclude that activation of the heat shock response is not required to mediate the effect of Sirt1 inhibition on the suppressive functions of Tregs.

HDAC6 has intranuclear functions and deacetylates Foxp3

Given our finding that pharmacologic targeting of Sirt1 improved Treg function independently of the heat shock response, we hypothesized that HDAC6 might also have roles in Treg biology that were independent of the heat shock response. Whereas HDAC6 is regarded primarily as a cytosolic protein that regulates the acetylation of cytoskeletal proteins such as α-tubulin, we found that HDAC6 translocated to the nucleus of Tregs activated through CD3ε and the co-receptor CD28 (Fig. 2A). This observation suggested that HDAC6 might have nuclear functions, such that targeting HDAC6 might affect the extent of acetylation of nuclear proteins relevant to Treg function. Indeed, we found that the Foxp3 protein was more abundant in HDAC6−/− Tregs than in wild-type Tregs (Fig. 2B), that it coimmunoprecipitated with HDAC6 (Fig. 2C), and that there was more acetylated Foxp3 in the absence of HDAC6 than in its presence (Fig. 2, D to F). These data suggest that HDAC6 deacetylates Foxp3 and that loss of HDAC6 promotes Foxp3 acetylation, with a consequent increase in the resistance of Foxp3 to proteasomal degradation (14). HDAC6 may also contribute to the regulation of additional transcription factors required for Tregs (figs. S2 and S3), including promoting the nuclear translocation of cyclic adenosine monophosphate (cAMP) response element–binding protein (CREB) phosphorylated at Ser133 (S133). We conclude that HDAC6 has important heat shock response–independent functions in Tregs, including regulating the acetylation of Foxp3.

Fig. 2

Functions of HDAC6 in Foxp3+ Tregs that are independent of the heat shock response. (A) Immunofluorescence showing the translocation of HDAC6 into the nuclei of WT Tregs after stimulation with antibodies against CD3ε and CD28. (B) Western blotting analysis of Treg lysates indicated that Foxp3 is more abundant in HDAC6−/− cells than in WT cells. Densitometry data are pooled from three experiments. (C) Coimmunoprecipitation of HDAC6 and Foxp3 in WT Treg lysates. IgG, immunoglobulin G. (D) Immunoprecipitation studies of Treg lysates indicated that Foxp3 is more acetylated in HDAC6−/− Tregs than in WT Tregs. Densitometry data are pooled from two experiments. (E) Proximity ligation assays showed more acetylated Foxp3 in HDAC6−/− Tregs than in WT Tregs. DAPI, 4′,6-diamidino-2-phenylindole. (F) Quantification of proximity ligation assays with BlobFinder and statistical analysis with the Kruskal-Wallis test. *P < 0.05; ***P < 0.001. Data shown as box plot with the median, 25th, and 75th quartiles; whiskers indicate the 10th and 90th percentiles. Scale bars, 10 μm.

Loss of HDAC9 promotes STAT5 acetylation and Treg phenotype

The transcription factor signal transducer and activator of transcription 5 (STAT5), which transduces signals resulting from the binding of interleukin-2 (IL-2) to the IL-2 receptor (IL-2R), is important for the functions of Foxp3+ Tregs (16). We showed that HDAC9−/− CD4+CD25 effector T cells more readily convert into induced Tregs (iTregs) than do the corresponding wild-type effector T cells when stimulated with transforming growth factor–β (TGF-β) (15). Such a predisposition to iTreg conversion does not occur for effector T cells from fl-Sirt1/CD4cre mice (fig. S4), supporting the hypothesis that each HDAC might affect different aspects of Treg biology. Because IL-2 signaling is important in stabilizing iTregs (17), we hypothesized that acetylation of the downstream IL-2 target, STAT5, might determine the differential abilities of HDAC9−/− and Sirt1−/− T cells to undergo conversion to iTregs (Fig. 3A). Indeed, we found increased phosphorylation of STAT5 [Tyr694 (Y694)] (Fig. 3B) and increased acetylation of STAT5 (Fig. 3, C and D) in HDAC9−/− Tregs compared to wild-type Tregs, as was the case to a lesser degree in a comparison of fl-Sirt1/CD4cre Tregs and wild-type Tregs.

Fig. 3

Deletion of HDAC9 stabilizes the acetylation, phosphorylation, and transcriptional activity of STAT5. (A) Conceptual model of the acetylation of STAT5, which protects it from losing its transcriptionally active, phosphorylated dimeric form. (B) Analysis of Treg lysates indicated that STAT5 was relatively more phosphorylated in HDAC9−/− cells than in WT cells. Densitometry data are pooled from three experiments. (C) Proximity ligation assay showed prominent acetylation of STAT5 in HDAC9−/− Tregs compared to that in WT Tregs. (D) Quantification of the data in (C) was performed as described for Fig. 2F. (E) Microarray analysis showed STAT5-dependent signaling in HDAC9−/− Tregs compared to WT Treg (n = 3 mice per group) on the basis of previously reported STAT5 targets (19). (F) Further STAT5 signaling as well as other transcriptional alterations promoted a suppressive phenotype in HDAC9−/− Tregs. Data are shown after z score transformation. *IL-10, not significant; ***P < 0.001. Scale bar, 10 μm. Trp, transformation-related protein; Mcl, myeloid leukemia cell-differentiating protein; Tnfsf, tumor necrosis factor superfamily; Id, inhibitor of DNA; Lta, lymphotoxin-α; Nos, nitric oxide synthase; Mdm2, an E3 ubiquitin ligase; Scl2a1, GLUT1; Trim, tripartite motif; Klk, kallikrein; ptgs, posttranscriptional gene silencing; bmp2k, bone morphogenetic protein inducible kinase-2; Cd2ap, CD2-associated protein; Ikbke, inhibitor of NF-κB kinase ε; Iigp, interferon-inducible guanosine triphosphatase (GTPase); Xiap, X-linked inhibitor of apoptosis; Fas, CD95; Bcl, B cell lymphoma; mettl, methyltransferase-like; St8sia, ST8 α-N-acetyl-neuraminide α-2,8-sialyltransferase-4.

We then assessed whether increases in STAT5 phosphorylation and acetylation were associated with decreased methylation of the Treg-specific demethylated region (TSDR) in effector T cells, which has been proposed as a methylation-sensitive region that controls expression of the gene encoding Foxp3 (18). However, pyrosequencing of six key CpG islands within the TSDR did not show any difference in methylation between wild-type Tregs and Tregs deficient in HDAC6, HDAC9, or Sirt1 (figs. S5 and S6). Upon checking the expression of known STAT5-dependent transcripts by microarray analysis, we noted that HDAC9−/− Tregs had a pattern of differential gene expression that was opposite to that of a STAT5 knockdown model reported by Liao et al. (19), supporting our concept of the increased transcriptional activity of STAT5 in HDAC9−/− Treg cells (Fig. 3E). Additional transcripts were altered in HDAC9−/− Tregs showing increased expression of several transcripts associated with the Treg phenotype (Fig. 3F). We conclude that loss of HDAC9 promotes STAT5 signaling in Tregs. Together, our data suggest that HDAC6, HDAC9, and Sirt1 have shared and individual mechanisms of action in increasing the suppressive activities of Tregs. We continued our investigation by combining the targeting of these HDACs with the goal of optimizing the suppressive capacity of Tregs.

Combined loss of HDAC6, HDAC9, and Sirt1 augments Treg function

The clinical use of pharmacologic inhibitors of HDACs has primarily been limited to oncologic applications because of the toxicities and side effects of existing pan-HDAC inhibitors (20). Because we wished to investigate the usefulness of simultaneously targeting specific HDAC proteins in Tregs, and there are, as yet, no specific HDAC9 inhibitors, we combined genetic and pharmacologic approaches with HDAC6−/− and Sirt1−/− mice and the isotype-specific HDAC inhibitors ACY-738 (HDAC6) and EX-527 (Sirt1). We found that the suppressive functions of Tregs from HDAC6−/− or fl-Sirt1/CD4cre mice were augmented by the addition of the complementary HDAC inhibitor (Fig. 4A). Furthermore, this additive benefit was also observed in wild-type Tregs treated with combined HDAC6 and Sirt1 inhibitors simultaneously, which achieved better suppression than did treatment with either HDAC inhibitor alone (Fig. 4B). Similarly, we developed HDAC6 and HDAC9 double-knockout mice and found that Treg function was further strengthened compared to those of Tregs from either single-knockout or wild-type mice (Fig. 4C). Combining the targeting of HDAC9 and Sirt1 led to only a marginal improvement in the suppressive function of Tregs (fig. S7). Furthermore, loss of three HDACs (which was achieved by treating HDAC9−/− mice with inhibitors of both HDAC6 and Sirt1) did not further augment Treg function compared to that of Tregs treated with inhibitors of HDAC6 or Sirt1 alone (fig. S8). Therefore, we focused our present investigation on the effects of targeting both HDAC6 and HDAC9 or both Sirt1 and HDAC6.

Fig. 4

Combined targeting of HDACs can further augment the suppressive function of Tregs. (A) Treg suppression assays with WT effector T cells and APCs, as well as with WT or HDAC-deficient Tregs with or without one or two specific HDAC inhibitors. We used EX-527 (5 μM) and ACY-738 (1 μM) to inhibit Sirt1 and HDAC6, respectively. (B) WT Tregs treated with Sirt1i, HDAC6i, or both showed increased suppressive function compared to Tregs treated with single HDAC6i or Sirt1i or vehicle control. (C) HDAC6−/−HDAC9−/− double-knockout Tregs showed stronger suppressive function compared with WT and single-knockout Tregs. Data are representative of three independent experiments.

Combined inhibition of Sirt1 and HDAC6 has an additive effect in improving Treg function in vivo

To extend our findings of combined pharmacologic inhibition of HDAC6 and Sirt1 inhibition in vivo, we adoptively transferred Thy1.1 (CD90.1+) CD4+CD25 effector T cells into B6/Rag1−/− mice and administered wild-type CD4+CD25+ Tregs at a 1:4 ratio. In this model, Thy1.1 effector T cells are injected into immunocompromised mice lacking host T and B cells. The injected effector T cells proliferate rapidly but are limited in their expansion by the coadministered Tregs. The mice were then treated with dimethyl sulfoxide (DMSO) as a vehicle control or with Sirt1 and HDAC6 inhibitors, either alone or in combination. Cotreatment with Sirt1 and HDAC6 inhibitors was most effective at suppressing the proliferation of the adoptively transferred effector T cells and was stronger than was the inhibition of either Sirt1 or HDAC6 alone (Fig. 5A). This was associated with less proliferation of host non-CD4 cells (Fig. 5, B and C), improved preservation of Foxp3+ Tregs, and increased proliferation of the injected Treg population (Fig. 5, D and E). Treatment with the inhibitors Sirt1i, HDAC6i, or both did not affect the induction of Foxp3+ Tregs from the injected Thy1.1 effector T cells (Fig. 5F) and did not affect the proliferation of effector T cells (fig. S9). We conclude that combining the targeting of Sirt1 and HDAC6 produces an additive increase in Treg suppressive function in vivo.

Fig. 5

Combined pharmacologic targeting of HDAC6 and Sirt1 is additive in improving the suppressive function of Tregs on T-effector (TE) cells and preserving Foxp3 in vivo. (A) Homeostatic proliferation assays showed increased suppressive function of Tregs in mice after individual treatment with either Sirt1i [EX-527, 1 mg/kg per day intraperitoneally (ip)] or HDAC6i (Tubastatin, 40 mg/kg per day ip) as well as further improvement with combined treatment. (B) Gating strategy to identify cell populations of interest in spleens harvested from B6/Rag1−/− mice; combined treatment sample shown. Red-labeled boxes identify populations of cells subsequently analyzed in the indicated panels. (C) Ki67 is reduced in host non-CD4+ cells treated with Sirt1i or HDAC6i. (D) Foxp3+ was better preserved in Tregs from mice treated with Sirt1i and HDAC6i, especially in combination, than in untreated mice. (E) Tregs from mice treated with Sirt1i, HDAC6i, and combined treatment groups had a more activated phenotype (Ki67) than did untreated cells. (F) Neither Sirt1i nor HDAC6i improved the induction of Tregs from effector T cells. Data are from three mice per group (n = 15). *P < 0.05; **P < 0.01; ***P < 0.001. ns, not significant.

Next, we conducted a similar homeostatic proliferation experiment to compare HDAC6−/−, HDAC9−/−, HDAC6−/−HDAC9−/− double-knockout Tregs, and wild-type controls. Unlike the case with pharmacologic targeting of Sirt1 and HDAC6, the double-knockout HDAC6−/−HDAC9−/− Tregs did not further suppress effector cell proliferation anymore than did either single knockout in vivo (Fig. 6A). In contrast to the combined inhibition of Sirt1 and HDAC6, Foxp3 preservation within the injected Tregs was not altered (Fig. 6B), although we observed a trend with HDAC6−/− cells that was consistent with a similar change in cells treated with HDAC6i (Fig. 5D). Lastly, we noted that the abundance of the proliferation marker Ki67 was higher in HDAC6−/−HDAC9−/− double-knockout Tregs than in single HDAC6 or HDAC9 knockout mice or in wild-type Tregs (Fig. 6C). Thus, we conclude that the combined targeting of HDAC6 and Sirt1 is so far the most promising lead to achieve additive improvement in Treg function.

Fig. 6

Combined genetic targeting of HDAC6 and HDAC9 does not substantially improve the suppressive function of Tregs in vivo. (A) Homeostatic proliferation assays showed improved suppression of effector T cells by Tregs with either individual deficiency in either HDAC6 or HDAC9, but no added benefit from combined deletion. (B) Preservation of Foxp3 was not changed by combined knockout of HDAC6 and HDAC9. (C) Ki67 abundance was increased in HDAC6−/− HDAC9−/− double-knockout Tregs compared to that in Tregs from single-knockout and WT mice. Data are from three to four mice per group (n = 18). The gating strategy used was similar to that in Fig. 5B. *P < 0.05; **P < 0.01; ***P < 0.001. ns, not significant.

Discussion

To move beyond the limitations of contemporary immunotherapies, the induction and maintenance of tolerance will need to become central components of future immunosuppressive regimens. To that end, direct administration of Tregs and the use of pharmacological agents that support Treg function hold substantial promise (20). However, current regimens for increasing the numbers of Tregs ex vivo face a number of challenges, among them the relatively short-lived persistence of the Treg phenotype in vivo (21). Augmenting the number or efficiency of endogenous Tregs through the use of HDAC inhibitors is an attractive alternative to the administration of ex vivo expanded or induced Tregs and may also be relevant to stabilizing their phenotype after administration to the patient (22). Here, we identified multiple HDACs that are suitable targets for inhibition and have tested several HDAC inhibitors, both class- and isotype-specific, with in vitro and in vivo models. However, because the network of HDAC interactions and their roles in Treg biology remain ill-defined, and because suppression of certain HDAC isoforms may even worsen Treg function, a strategy that focuses on the inhibition of Sirt1, HDAC6, and HDAC9 is both logical and feasible (11). Our findings support the concept that these three HDACs share common mechanisms (for example, the deacetylation of Foxp3), but they also have distinctly different effects on Treg biology (for example, the heat shock response and transcription factors controlling expression of the gene encoding Foxp3). Our studies showed that HDAC6 can regulate Foxp3 acetylation, which is a signature mechanism of action of several HDACs in Tregs (8, 10, 13, 23, 24). Acetylation of Foxp3 is an important posttranslational mechanism that affects Foxp3 abundance because it protects Foxp3 from K48-mediated polyubiquitination and proteasomal degradation (13). In addition to extending the half-life of the Foxp3 protein, acetylation increases its DNA binding capability, which leads to enhanced suppressive function of Tregs (25).

Important differences in the actions of the individual HDACs in Tregs are also apparent from our studies. The most important mechanism for the enhancement of Treg function as a result of HDAC6 inhibition appears to be the induction of the heat shock response. Activation of the heat shock response enables the production of chaperone proteins, such as Hsp27 and Hsp70, which protect the cell from stresses such as hypoxia or hyperthermia, and could give Tregs with an improved heat shock response a “survival advantage” under inflammatory conditions. Indeed, we found that Hsp70-depleted Tregs had decreased suppressive function compared to that of wild-type control Tregs. Although DNA binding by the HSF-1 trimer is stabilized by Sirt1 (12), and deletion of Sirt1 led to a diminished heat shock response, this effect did not impair the survival of Sirt1−/− Tregs under heat shock. We hypothesized that Sirt1 might deacetylate Hsp70 and thereby influence the cellular heat shock response at a posttranslational level because acetylation of Hsp70 increases its chaperone activity (26); however, we could not detect increased Hsp70 acetylation in cells lacking Sirt1. Even if the acetylation of Hsp70 were enhanced in the absence of Sirt1, the importance of Hsp70 for the functional improvement of Tregs in which Sirt1 is inhibited appeared minimal. This is a central point because it provides a rationale for combining inhibition of HDAC6 with that of Sirt1, despite their apparently contrary effects on the heat shock response, to achieve optimized inhibition of Tregs.

Diversity in the effects of HDACs was also apparent at the level of transcription factors that affect the abundance of Foxp3. Although the net result of deleting HDAC6, HDAC9, or Sirt1 is a similar increase in the expression of the gene encoding Foxp3 (810), the transcription factors involved are different. Loss of Sirt1 stabilizes the acetylation of K310 of p65 (10), which increases its transcriptional activation (27), and is consistent with the nuclear translocation of p65 in fl-Sirt1/CD4cre Tregs that we observed (fig. S2). On the other hand, loss of HDAC9 favored the acetylation of STAT5. STAT5 has three reported acetylation sites (K694, K701, and K359), which, when acetylated, stabilize the transcriptionally active STAT5 dimer (28). Thus, the abundance of STAT5 Y694 phosphorylation, which is responsible for STAT5 nuclear translocation (29), may be secondary because of the stabilized STAT5 dimer being protected from dephosphorylation. Lastly, our study demonstrated the usefulness of combined targeting of HDACs by genetic deletion, the use of two isotype-specific HDAC inhibitors, or both approaches. Hence, targeting selected HDACs in combination is a promising strategy to augment Treg function and with potentially less toxicity than occurs through the use of one or more pan-HDAC inhibitors. Because the combined pharmacologic inhibition of HDAC6 and Sirt1 was most effective in our in vivo studies, and because isotype-selective inhibitors are commercially available, this combination is, for the time being, the best lead to achieve this goal. Our study provides a rationale for further testing of combinations of isotype-specific HDAC inhibitors with relevant in vivo models, as well as in vitro studies with human cells.

Materials and Methods

Mice

C57BL/6 and B6/Rag1−/− (Jackson Laboratory), B6/129 (Taconic), HDAC6−/− (30), HDAC9−/− (31), fl-Sirt1/CD4cre (10), fl-Sirt1/Foxp3cre (10), and Hsp70−/− (32) mice, all on an H-2b background, were housed under specific pathogen–free conditions and were studied under a protocol approved by the Institutional Animal Care and Use Committee of the Children’s Hospital of Philadelphia.

Antibodies and small molecules

For flow cytometric analysis, we purchased mAbs against murine CD4 [conjugated to APC-eFluor 780, phycoerythrin (PE)], CD8 (PE-Cy7), CD25 (PE-Cy5), and Foxp3 (APC, PE) from eBioscience and against CD4 (Pacific Blue) and CD90.1 (PE-Cy7) from BD Pharmingen. For Western blotting and fluorescence studies, we purchased antibodies against Sirt1, Hsp90, acetyl lysine, STAT5 (recognizing both α and β forms), phosphorylated STAT5 (pSTAT5, Y694), Smad3, pSmad3 (S423/425), pCREB (S133), and CREB from Cell Signaling. We also purchased antibodies against acetyl-Hsp90 (K294, Rockland), Foxp3 (eBioscience), and β-actin from Santa Cruz. EX-527 was purchased from Tocris Bioscience, and the HDAC6 inhibitor compounds, Tubastatin and ACY-738, were provided by A. Kozikowski (University of Illinois at Chicago) and Acetylon Pharmaceuticals, respectively. Small molecules were dissolved in DMSO, and DMSO alone was used as a control.

Cell isolation, flow cytometry, and pyrosequencing

Spleens and somatic lymph nodes were harvested from mice and processed to a single-cell suspension of lymphocytes. We used magnetic beads (Miltenyi Biotec) for the isolation of CD4+CD25 effector T cells, CD4+CD25+ Tregs, CD8+ T cells, and Thy1.2 APCs. Cells of interest were analyzed for their surface markers. For detection of Foxp3, cells that had been stained for surface markers were fixed, permeabilized, and labeled with Foxp3-specific mAb (33). Data were analyzed with FlowJo 6.4.7 software (TreeStar). Pyrosequencing of TSDR methylation in isolated effector T cells was performed by EpigenDx (assay ID: ADS443FS2).

Analysis of T cell function

For Treg suppression assays, purified effector T cells were labeled with carboxyfluorescein succinimidyl ester (CFSE, Molecular Probes) and stimulated with irradiated APCs and antibody against CD3ε (1 μg/ml, BD Pharmingen). After 72 hours, cells were labeled with fluorescent mAb against CD4 and analyzed by flow cytometry. For quantification, we normalized relative suppression and calculated areas under the curve as previously reported (7). To measure the extent of conversion of effector T cells into Foxp3+ Tregs, we incubated effector T cells with TGF-β (3 ng/ml) and IL-2 (25 U/ml) for 4 days and then assessed the cells by flow cytometry for the presence of Foxp3+ (15). For in vivo Treg suppression assays, we adoptively transferred Thy1.1+ CD4+ effector T cells in the presence or absence of Tregs into B6/RAG1−/− mice at a 4:1 ratio (8). Lymphocytes were isolated after 1 week, and the increase in numbers of cells identified by the markers Thy1.1, CD4, Foxp3, and Ki67 was assessed by flow cytometry.

Immunofluorescence staining

We centrifuged freshly isolated CD4+CD25+ Tregs or CD4+CD25+ Tregs that had been treated for 2 hours with antibodies against CD3ε and CD28 onto cytospin slides (Fisherfinest; Thermo Fisher Scientific). We permeabilized the cells with 10% normal goat serum and 1% Triton X. Double-stranded DNA was visualized with Hoechst 33342 (Invitrogen). Images were obtained with an Olympus BX51 Brightfield microscope (Olympus) at 100× magnifications. All raw images were universally processed with Adobe Photoshop 7.0 with the autocontrast feature and were merged with ImageJ 1.44 (National Institutes of Health, http://rsbweb.nih.gov/ij/) as shown in fig. S10A.

Western blotting analysis

After cell lysis in radioimmunoprecipitation assay (RIPA) buffer with Halt protease inhibitor (Thermo Fisher Scientific) and the determination of protein concentration (DU640, Beckman-Coulter), samples were mixed with Laemmli sample buffer containing 2-mercaptoethanol (Bio-Rad) and boiled for 5 min. Samples were loaded onto Mini-PROTEAN TGXT 4 to 15% gradient gels (Bio-Rad), and after separation (at 200 V for 30 min), proteins were transferred to PolyScreen PVDF Hybridization Transfer Membranes (PerkinElmer). Membranes were cut according to the molecular weights of the proteins of interest (as indicated with Precision Plus Protein Dual Color, Bio-Rad) and incubated with primary and horseradish peroxidase (HRP)–conjugated secondary antibodies. We used SuperSignal West Pico chemiluminescent substrate (Thermo Fisher Scientific) and X-OMAT Blue XB Film (Kodak) for image development. Depending on the background, films were scanned or photographed and then processed with Adobe Photoshop 7.0 (grayscale conversion and autocontrast function; see fig. S10B). Densitometric analysis was performed with ImageJ 1.44.

Proximity ligation assays

We prepared cytospin slides of CD4+CD25+ Tregs and used primary antibodies as described earlier. Antibodies against acetyl lysine and either STAT5 or Foxp3 were chosen to be matching mouse- and rabbit-based antibodies (that is, mouse mAb against Foxp3 was combined with a rabbit antibody against acetyl lysine, and the rabbit mAb against STAT5 was matched with a mouse antibody against acetyl lysine). Subsequently, we used a Duolink in situ proximity ligation assay kit, “Orange” (Olink Bioscience), with corresponding secondary antibodies (PLUS-rabbit, MINUS-mouse), according to the manufacturer’s instructions. We quantified the data with BlobFinder software by Allalou and Wählby (Centre for Image Analysis, Uppsala, Sweden, http://www.cb.uu.se/~amin/BlobFinder/) (34).

Microarrays

RNA was extracted with RNeasy kits (Qiagen), and RNA integrity and quantity were analyzed by photometry (DU640; Beckman-Coulter). Microarray experiments were performed with whole-mouse genome oligoarrays (Mouse 430a 2.0; Affymetrix), and array data were analyzed with Mayday 2.12 software (35). Array data were subjected to robust multiarray average normalization. Normalized data were used for calculating fold changes of genes that were increased or decreased in expression with the Student’s t test, and data with greater than twofold differential expression (P < 0.05 with Storey’s false discovery rate <0.1) were included in the analysis. Data underwent z score transformation for display.

Statistical analysis

Data were analyzed with GraphPad Prism 5.0d software. All normally distributed data were displayed as means ± SD. Measurements between two groups were performed with a Student’s t test or Mann-Whitney U test. Groups of three or more were analyzed by one-way analysis of variance (ANOVA) or the Kruskal-Wallis test.

Supplementary Materials

www.sciencesignaling.org/cgi/content/full/5/229/ra45/DC1

Fig. S1. ACY-738 and Tubastatin are HDAC6 inhibitors.

Fig. S2. Immunofluorescence analysis of Tregs to assess the cytosolic and nuclear localization of Foxp3.

Fig. S3. Western blotting analysis of Treg lysates to compare Foxp3 transcription factors.

Fig. S4. Loss of Sirt1 does not affect conversion to iTregs.

Fig. S5. Loss of HDAC9 does not alter TSDR methylation.

Fig. S6. Purity control of the effector T cells used for the pyrosequencing methylation assay (fig. S5).

Fig. S7. Combined deletion of Sirt1 and HDAC9 produces minor improvements in Treg function.

Fig. S8. Targeting of three HDACs does not improve Treg function any more than does use of dual HDACi.

Fig. S9. Proliferation of effector T cells is not affected by HDAC inhibitors.

Fig. S10. Examples of image processing.

Table S1. Statistical analysis for Fig. 1C.

Table S2. Statistical analysis for Fig. 1G.

References and Notes

Funding: The project described was supported by award numbers K08AI095353 (to U.H.B.), AI073489, and AI095276 (to W.W.H.) from the National Institute of Allergy and Infectious Diseases. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Allergy and Infectious Diseases or the NIH. Author contributions: U.H.B. and W.W.H. conceived the study and designed the experiments. U.H.B. and L.W. did most of the experiments. R.H. prepared immunofluorescence staining. T.A. and Y.L. assisted with homeostatic proliferation assays and advised with flow cytometry and protein biochemistry assays. U.H.B., L.W., T.A., Y.L., and W.W.H. analyzed the data. U.H.B. wrote the manuscript, and W.W.H. edited the manuscript. Competing interests: The authors declare that they have no competing interests. Data and materials availability: Data were deposited in the National Center for Biotechnology Information Gene Expression Omnibus database (http://www.ncbi.nlm.nih.gov/geo) under accession numbers GSE26425 and GSE36095.
View Abstract

Navigate This Article